PF-Atlas › Clinical Trials › NCT03218917

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Brensocatib 10 mg · Phase 2

Registry ID
NCT03218917
Phase
Phase 2
Status
Completed
Drug / intervention
Brensocatib 10 mg
Sponsor
Insmed Incorporated
Start
2017-10-31
Enrollment
256
Locations
108

About this trial

The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.

View NCT03218917 on ClinicalTrials.gov →

Explore related

All Brensocatib 10 mg trialsAll IPF trials

Related trials

Brensocatib 10 mg — NCT04594369
Medical disclaimer. This page summarizes public trial data for NCT03218917 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.